VIBOSTOLIMAB PLUS PEMBROLIZUMAB WITH/WITHOUT DOCETAXEL VS DOCETAXEL IN NSCLC AFTER PLATINUM CHEMOTHERAPY AND IMMUNOTHERAPY

被引：0

作者：

Peters, Solange ^{[1
]}

Lee, Dae Ho ^{[2
]}

Ramlau, Rodryg ^{[3
]}

Halmos, Balazs ^{[4
]}

Schumann, Christian ^{[5
]}

Planchard, David ^{[6
]}

Bhagwati, Niyati ^{[7
]}

Chen, Diana ^{[7
]}

Kush, Debra ^{[7
]}

Novello, Silvia ^{[8
]}

机构：

[1] Univ Lausanne, Ctr Hosp Univ Vaudois, Lausanne, Switzerland

[2] Asan Med Ctr, Seoul, South Korea

[3] Poznan Univ Med Sci, Poznan, Poland

[4] Montefiore Einstein Ctr Canc Care, Dept Oncol, New York, NY USA

[5] Klin Pneumol Thoraxonkol Schlaf & Beatmungsmed, Klinikverbund Allgau, Kempten, Germany

[6] Dept Med Oncol, Thorac Grp, Gustave Roussy, Villejuif, France

[7] Merck & Co Inc, Kenilworth, NJ USA

[8] Gonzaga Univ Turin, Azienda Osped Univ San Luigi, Dept Oncol, Orbassano, Italy

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷

关键词：

D O I：

10.1136/jitc-2021-SITC2021.463

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

463

引用

页码：A492 / A492

页数：1

共 50 条

[21] Plinabulin/Docetaxel vs. Docetaxel in 2L/3L NSCLC after Platinum Regimens (DUBLIN-3): A Phase 3 Randomized Controlled Trial
Feinstein, T.
Han, B.
Shi, Y.
Chen, G.
Yao, Y.
Hu, C.
Shi, J.
Feng, J.
Wu, H.
Chen, Y.
Guo, Q-S.
Jie, Z.
Ye, F.
Zhang, Y.
Liu, Z.
Mao, W.
Zhang, L.
Lu, J.
Zhao, J.
Bazhenova, L.
Ruiz, J.
Kloecker, G.
Kalmadi, S.
Oliff, I.
Wong, M.
Liu, B.
Wu, Y.
Huang, L.
Sun, Y.
Luo, F.
Zhou, J-Y.
Pan, H.
Wang, H.
Liu, C.
Cao, L.
Huang, C.
Thara, E.
Li, X.
Jiang, D.
Mowat, R. B.
Hrom, J. S.
Nagrial, A.
Jain, V.
Karim, N. A.
Shunyakov, L. V.
Kiberu, A.
Jennens, R.
Lloyd, K.
Wang, Z.
Du, L.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S24 - S25
[22] Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC
Westeel, Virginie
Schuette, Wolfgang
Urban, Thierry
Radonjic, Dejan
von Wangenheim, Ute
Lorence, Robert M.
Reck, Martin
PLOS ONE, 2023, 18 (10):
[23] Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy
Hochmair, Maximilian
Schenker, Michael
Dols, Manuel Cobo
Kim, Tae Min
Ozyilkan, Ozgur
Smagina, Maria
Leonova, Viktoriya
Kato, Terufumi
Fedenko, Alexander
De Angelis, Flavia
Rittmeyer, Achim
Gray, Jhanelle E.
Greystoke, Alastair
Aggarwal, Himani
Huang, Qinlei
Zhao, Bin
Lara-Guerra, Humberto
Nadal, Ernest
JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (02) : 203 - 218
[24] A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine
Lee, Keun-Wook
Kim, Bum Jun
Kim, Mi-Jung
Han, Hye Sook
Kim, Jin Won
Park, Young Lee
Park, Sook Ryun
CANCER RESEARCH AND TREATMENT, 2017, 49 (03): : 706 - 716
[25] A multicenter randomized phase II study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus either S-1 or capecitabine
Kim, B.
Lee, K. W.
Kim, M. J.
Han, H. S.
Park, Y. L.
Park, S. R.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S432 - S432
[26] Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
Chen, Ya
Yang, Zhengyu
Wang, Yanan
Hu, Minjuan
Zhang, Bo
Zhang, Yanwei
Qian, Fangfei
Zhang, Wei
Han, Baohui
FRONTIERS IN ONCOLOGY, 2021, 11
[27] KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1-positive NSCLC after platinum-based therapy
Herbst, R. S.
Kim, D-W.
Felip, E.
Perez-Gracia, J. L.
Garon, E. B.
Han, J-Y.
Molina, J.
Kim, J-H.
Gervais, R.
Ahn, M-J.
Majem, M.
Fidler, M. J.
De Castro, G., Jr.
Garrido, M.
Lubiniecki, G. M.
Shentu, Y.
Im, E.
Baas, P.
ANNALS OF ONCOLOGY, 2015, 26 : 162 - 162
[28] Comparison of Efficacy and Safety Between Immunotherapy and Docetaxel Monotherapy in NSCLC Patients
Yang, Wenchao
Xuan, Bixia
Chen, Mengqi
Li, Xiaofang
He, Jiana
Si, Haiyan
Zhang, Yefei
FRONTIERS IN ONCOLOGY, 2022, 12
[29] Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
Sun, Xue-Song
Wang, Xiao-Hao
Liu, Sai-Lan
Luo, Dong-Hua
Sun, Rui
Liu, Li-Ting
Guo, Shan-Shan
Chen, Qiu-Yan
Tang, Lin-Quan
Mai, Hai-Qiang
FRONTIERS IN ONCOLOGY, 2020, 10
[30] DOCETAXEL - RECHALLENGE AT PSA RELAPSE AFTER DOCETAXEL CHEMOTHERAPY AT HORMONE REFRACTORY PROSTATE CANCER
Firek, Peter
Pfister, David
Thueer, David
Brehmer, Bernhard
Epplen, Robin
Heidenreich, Axel
JOURNAL OF UROLOGY, 2010, 183 (04): : E263 - E263

← 1 2 3 4 5 →